Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Genmab

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus

Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus

Genmab, on Monday, announced its plan to buy Merus for about $8 billion. The news sent Merus stock into the stratosphere.

Investors Business Daily

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab A/S (NASDAQ:GMAB) released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Should You Be Investing in Nordic Companies?

Should you be Investing in Nordic companies? This corner of Europe presents unique opportunities for investors.

Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover

Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.

Investors Business Daily

Top Biotech 3 Stocks With Accelerating Profits

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark

Genmab ADR sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Holds Gains; Fed, CPI On Deck; IBD 50 Leads With Breakout Among Its Stocks

Dow Jones Holds Gains; Fed, CPI On Deck; IBD 50 Leads With Breakout Among Its Stocks

Dow Jones rises ahead of last 2022 Fed meeting. IBD 50 stocks Box, Genmab, Allegro and AGCO on watch; CPI on Tuesday.

Investors Business Daily

Dow Jones Turns Higher As Stocks Pare Losses; Solar Stocks Rise; Russia Oil Cap Set At $60; Tesla's First Semi Lands At PepsiCo's Door

Dow Jones Turns Higher As Stocks Pare Losses; Solar Stocks Rise; Russia Oil Cap Set At $60; Tesla's First Semi Lands At PepsiCo's Door

Dow Jones industrials reversed higher in late trading; Tesla delivered its first cybertruck to Pepsi; solar stocks surged; the cap on Russian oil was put at $60 a barrel.

Investors Business Daily

Oil Firm Eyeing 3,755% Q4 Growth Leads 24 Fastest-Growing Stocks

Oil Firm Eyeing 3,755% Q4 Growth Leads 24 Fastest-Growing Stocks

With analysts expecting a whopping 3,755% Q4 growth, HF Sinclair leads this list of 24 of today's fastest-growing stocks.

Investors Business Daily

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Here's a roundup of top developments in the biotech space over the last 24 hours:

Where Genmab Stands With Analysts

Where Genmab Stands With Analysts

Analysts have provided the following ratings for Genmab (NASDAQ:GMAB) within the last quarter:

Analyst Ratings for Genmab

Analyst Ratings for Genmab

Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022

Get all your
news in one place.

100’s of premium titles.
One news app.

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

Johnson & Johnson's (NYSE:JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ:GMAB) on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab). The first issue around daratumumab arose because Janssen announced a deal with Halozyme Therapeutics Inc (NASDAQ: HALO) to develop a subcutaneous formulation of daratumumab. According to Janssen, Genmab must share…

The Daily Biotech Pulse: Evotec Earns $16M Milestone Payment, Genmab Hit With Adverse Tribunal Ruling, Quidel Announces Above-Consensus Q1 Revenues And More

Here's a roundup of top developments in the biotech space over the last 24 hours.

People

Alistair Campbell

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

312,385 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play